Summary Forty-three patients with large (> 4cm) but operable carcinoma of the breast have been treated by endocrine manipulation before definitive local surgery. This has allowed the study of the relationship between response to therapy and pretreatment oestrogen receptor (ER) concentration, as measured by a dextrancoated charcoal adsorption method. Premenopausal patients (17) were treated by surgical (4) or medical (13) oophorectomy. Post-menopausal patients (26) received either tamoxifen (10) The likelihood of response to endocrine treatment in patients with metastatic breast carcinoma is related to the concentration of oestrogen receptor (ER) protein within that tumour (McGuire et al., 1975; Brooks et al., 1980; Jensen, 1975; Dao & Nemoto, 1980; Oriana et al., 1987) . The value of ER status in predicting benefit from adjuvant endocrine treatment remains controversial. While several studies have demonstrated that only patients with ER-positive tumours have a significant survival advantage (Rose et al., 1985; Fisher et al., 1986; Rutquist et al., 1987; Meakin, 1986; Marshall et al., 1987; Bianco et al., 1988) , the Nato trial (Nolvadex Adjuvant Trial Organisation, 1988) with tumours of ER concentration 20 fmol mg-1 cytosol protein or less were given four cycles of the chemotherapeutic regime CHOP (cyclophosphamide 1 g m-2, adriamycin 50mgm -2, vincristine 1.4 mgm-2, prednisolone 40 mg orally 5 days).
The likelihood of response to endocrine treatment in patients with metastatic breast carcinoma is related to the concentration of oestrogen receptor (ER) protein within that tumour (McGuire et al., 1975; Brooks et al., 1980; Jensen, 1975; Dao & Nemoto, 1980; Oriana et al., 1987) . The value of ER status in predicting benefit from adjuvant endocrine treatment remains controversial. While several studies have demonstrated that only patients with ER-positive tumours have a significant survival advantage (Rose et al., 1985; Fisher et al., 1986; Rutquist et al., 1987; Meakin, 1986; Marshall et al., 1987; Bianco et al., 1988) , the Nato trial (Nolvadex Adjuvant Trial Organisation, 1988) has indicated that the benefit is independent of ER status. An intermediate view has been suggested by the Scottish (Scottish Cancer Trials Office (MRC) Edinburgh, 1987) and Copenhagen (Palshof et al., 1985) trials, in which all patients who received tamoxifen benefited but the level of benefit was greatest in those patients with tumours of an ER concentration of > 100fmol mg-1 cytosol protein. Thus the relationship between ER concentration and response of primary operable breast cancer to endocrine treatment remains uncertain.
We have previously reported (Forrest et al., 1986) The determination of oestrogen receptor concentration The ER concentration of the excised tumour specimen was determined using the dextran-coated charcoal adsorption method (Hawkins et al., 1981) . In brief, tumour was homogenised in tris-monothioglycerol-glycerol buffer and centrifuged at low speed; portions of tumour extract were incubated at 4°C overnight with eight concentrations of 3H oestradiol + non-radioactive oestradiol (0.031-62.3 nM). After separation of the bound fraction by adsorption with dextran-coated charcoal and scintillation counting, the concentration of receptor sites and dissociation constant of binding were calculated by Scatchard analysis (Scatchard, 1949 ) using a programmed BBC microcomputer. Protein concentration was determined in a separate portion of each tumour extract by the method of Bradford (Bradford, 1976) using serum albumin as a standard, with five quality controls. Receptor concentration was finally expressed as femtomol of binding sites per mg extract protein. Quality controls consisting of pools of minced human uterus were processed at least twice per week. Intra-assay precision was 3.9% but inter-assay precision was modest (25.1%, 33.6% on two tissue pools (Hawkins et al., 1987a) ).
Endocrine treatment In premenopausal patients (n= 17), suppression of ovarian function was achieved by either surgical bilateral oophorectomy (n = 4) or the administration of the gonadotrophin releasing-hormone agonist gosereliu (Zoladex; ICI 118630, subcutanesus implantation of 3.6mg depot preparation at 28 day intervals, n = 13).
Post-menopausal patients (n = 26) received either tamoxifen (20mg oral nocte, n = 10), or an aromatase inhibitor (n= 16). Initially aminoglutethimide 500mg plus hydrocortisone 40mg orally per day (n = 9) was used, but recently the selective peripheral aromatase inhibitor 4-hydroxyandrostenedione (Ciba-Geigy CGP 32349, 250mg intramuscular injection at 14-day intervals, n=7) has been preferred.
Assessment
During treatment, the patients were reviewed weekly by either EA or PL and the mean clinical tumour diameter was estimated. Single view mammography, in the plane known to give the best view of the tumour, was performed every 4 weeks.
Calculation of response Assessment of response was carried out at 12 weeks by analysis of the change in mean tumour diameter, as described previously (Forrest et al., 1986 ) with one refinement: the measurements recorded between treatment weeks I and 3 were disregarded to minimise any error introduced by the wedge biopsy. In brief, a regression line was calculated by least square analysis of the logs of the mean clinical diameters measured between treatment weeks 4 and 12 ( Figure 1 ). The statistical difference between the regression line and the horizontal was ascertained by application of Student's t test. Response was said to have occurred when there was a reduction in tumour size, and the probability that the regression slope deviated from the horizontal was >95%. The appearance of lymphoedema, or a statistically significant increase in tumour size, indicated progression. Tumours with regression slopes which lay between response and progression were categorised as 'no change'.
Local therapy
Those patients who had shown a response to endocrine treatment proceeded on to mastectomy with extensive skin removal (3cm clear of original tumour site), axillary node clearance and a latissimus dorsi myocutaneous flap reconstruction when required. Patients whose tumour remained static or in whom treatment required to be prematurely terminated due to progressive disease received four cycles of the chemotherapeutic regime CHOP before also proceeding to mastectomy.
Results
The spectrum of tumour ER concentrations in these patients is shown in relation to four subgroups (ER-negative 0-5 fmol mg-1 cytosol protein, ER-poor 5-19 fmol mg-1 cytosol protein ER-moderate 20-99fmolmg-1 cytosol protein and ER-rich > 100 fmol mg-1 cytosol protein) in Table I patients who progressed on treatment, except one, had tumours with an ER concentration of less than 20 fmolmg-1 cytosol protein (Figure 3) . This relationship held true for both premenopausal and post-menopausal patients.
Relationship between response and disease-free survival With a mean follow-up period of 40.6 months, eight patients have developed recurrent disease; two patients who responded to endocrine therapy and six patients who did not. Clinical response is related to disease-free survival in Figure  3 . Using the generalised Wilcoxon (Breslow) survival test, there was a statistical significant difference in survival between those patients who showed a response to endocrine treatment and those who did not (P<0.05). Figure 2 The relationship between the pretreatment ER concentration in 43 patients with primary operable carcinoma of the breast and clinical response to 3 months' treatment with endocrine therapy. -',Responders 
Discussion
This report confirms and expands our previous reports (Forrest et al., 1986; Hawkins et al., 1988; Anderson et al., 1989) (Gaskell et al., 1989) . Considering that this relationship also exists for metastatic disease (McGuire et al., 1975; Brooks et al., 1980; Jensen, 1975; Dao & Nemoto, 1980; Oriana et al., 1987) , it is reasonable to expect that ER concentration should be of value in selecting appropriate adjuvant endocrine therapy. We have already discussed the confusion which surrounds the value of ER activity in predicting benefit with adjuvant tamoxifen. In vitro studies have suggested that tamoxifen may have antitumour actions which are independent of the oestrogen receptor (Sutherland et al., 1986) and can be distinguished from nonspecific cytotoxicity by its cell cycle specific nature (Sutherland et al., 1983) . Thus results obtained using adjuvant tamoxifen cannot necessarily be extrapolated to other forms of endocrine therapy, e.g. oophorectomy. Further definition of the role of ER activity in predicting the benefit from adjuvant endocrine therapy is obviously required. This can only come from well conducted, controlled randomised trials designed specifically to answer this question and in which the performance of ER assays is of uniform high quality. Systemic therapy is of major importance in the long term control of invasive breast cancer because of the high possibility of micrometastatic disease at the time of initial presentation (Brinkley & Haybittle, 1984) . Since it is not yet possible to predict, on an individual basis, those patients who will benefit from a specific form of systemic therapy, there is theoretical value in giving systemic therapy as the preferred first line treatment. This would enable the response of the individual's tumour to be assessed and allow selection of appropriate systemic therapy. The availability of fineneedle aspiration techniques for diagnosis (Dixon et al., 1984) and more recently ER assay (Coombes et al., 1987; Hawkins et al., 1988; Anderson et al., 1989; Gaskell et al., 1989) should lend feasibility to this approach, avoiding the need for open biopsy. Kirkpatrick, Department of Medical Radiology and all of the medical and nursing staff of Longmore hospital for their care and concern. This research was supported by a grant from the Cancer Research Campaign (SP1256). The study was approved by the hospital ethical committee.
